Published in Can Med Assoc J on March 09, 1968
Significance of cryoprofibrin in fibrinogen-fibrin conversion. J Exp Med (1962) 2.15
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J Clin Invest (1962) 2.05
Cryopathies: a review. Classification; diagnostic and therapeutic considerations. Arch Intern Med (1961) 1.86
Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood (1955) 1.64
A heparin-precipitable fraction of human plasma. I. Isolation and characterization of the fraction. J Clin Invest (1957) 1.46
Cryofibrinogen: formation and inhibition in heparinized plasma. Am J Physiol (1963) 1.12
Cryofibrinogenemia. N Engl J Med (1962) 1.08
Interference of abnormal plasma proteins with the clotting mechanism. Am J Med (1957) 0.95
Cryofibrinogenemia. N Engl J Med (1960) 0.94
COLD-PRECIPITABLE FIBRINOGEN, "CRYOFIBRINOGEN". Arch Intern Med (1964) 0.92
Acute transient cryofibrinogenemia in infants. J Pediatr (1966) 0.85
Cryofibrinogenemia, multiple dysproteinemias, and hypervolemia in a patient with a primary hepatoma. Ann Intern Med (1966) 0.84
IDIOPATHIC (ESSENTIAL) CRYOFIBRINOGENEMIA. Tex Rep Biol Med (1963) 0.80
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med (1996) 5.20
Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation (1997) 4.81
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med (1993) 3.75
Clinical description and roentgenologic evaluation of patients with Friedreich's ataxia. Can J Neurol Sci (1976) 3.69
Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. Pediatrics (2001) 2.87
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74
Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA (1998) 2.28
Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med (2001) 2.22
L-dopa and juvenile Huntington's disease. Lancet (1969) 1.95
Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol (1998) 1.88
HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis (2000) 1.68
Predictive test for Huntington's chorea. Lancet (1970) 1.62
Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) Am J Cardiol (1995) 1.59
Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics (1993) 1.57
Angiotensin-forming enzyme in brain tissue. Science (1971) 1.55
Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology (1984) 1.55
Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation (1996) 1.54
Zinc, taurine, and epilepsy. Arch Neurol (1974) 1.52
Use of L-dopa in the detection of presymptomatic Huntington's chorea. N Engl J Med (1972) 1.51
Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA (1991) 1.50
Psychosocial factors at work, smoking, sedentary behavior, and body mass index: a prevalence study among 6995 white collar workers. J Occup Environ Med (2000) 1.50
Psychological stress and incidence of ischaemic heart disease. Int J Epidemiol (1999) 1.46
Dopamine and disease. Can Med Assoc J (1970) 1.44
Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Can J Neurol Sci (1978) 1.43
Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet (1985) 1.41
Free fatty acid oxidation by forearm muscle at rest, and evidence for an intramuscular lipid pool in the human forearm. J Clin Invest (1976) 1.40
The absolute nucleated red blood cell (aNRBC) count at birth is not an indicator for retinopathy of prematurity (ROP). J Perinatol (2012) 1.38
Friedreich's ataxia in the south of Italy: a clinical and biochemical survey of 23 patients. Can J Neurol Sci (1980) 1.38
Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Québec Cardiovascular Study) Am J Cardiol (1995) 1.36
Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia (2006) 1.33
Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol (1997) 1.30
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease. Neurology (1975) 1.29
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
Familial subsets in idiopathic Parkinson's disease. Can J Neurol Sci (1984) 1.27
Treatment of Parkinson's disease with levodopa and Ro 4-4602. Clin Pharmacol Ther (1971) 1.27
Recessive ataxia in Acadians and "Cajuns". Can J Neurol Sci (1984) 1.27
Renin-aldosterone system in Parkinson's disease. Science (1969) 1.26
Functional evaluation of prolactin secretion: a guide to therapy. J Clin Invest (1972) 1.22
Genetic and family studies in Friedreich's ataxia. Can J Neurol Sci (1976) 1.22
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J (1969) 1.21
Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med (2001) 1.20
Chronomes, time structures, for chronobioengineering for "a full life". Biomed Instrum Technol (1999) 1.20
Friedreich's ataxia 1976-an overview. Can J Neurol Sci (1976) 1.20
Role of manganese in dystonia. Adv Neurol (1976) 1.18
New data on the genetics of Parkinson's disease. Can J Neurol Sci (1982) 1.18
Survival of patients with a strongly positive exercise electrocardiogram. Circulation (1982) 1.16
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol (2005) 1.15
Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation (2001) 1.14
Letter: G.A.B.A. and Huntington's chorea. Lancet (1973) 1.14
A cluster of Friedreich's ataxia in Rimouski, Québec. Can J Neurol Sci (1979) 1.11
Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care (1998) 1.10
Coronary arteriographic appearances in patients with left bundle-branch block. Circulation (1970) 1.10
Relationship between the adrenergic nervous system and renin during adaptation to upright posture: a possible role for 3,4-dihydroxyphenethylamine (dopamine). Clin Sci (1972) 1.09
Influence of age and sex on exercise cardiac output. J Appl Physiol (1965) 1.08
[Incidence of arterial hypertension in the Quebec region]. Clin Invest Med (1983) 1.05
Long-term side-effects of levodopa. Lancet (1971) 1.04
Chronomics, neuroendocrine feedsidewards and the recording and consulting of nowcasts--forecasts of geomagnetics. Biomed Pharmacother (2005) 1.03
Nerve conduction studies and electromyography in Friedreich's ataxia. Can J Neurol Sci (1976) 1.03
[Treatment of essential familial tremor with propanolol]. Union Med Can (1973) 1.02
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol (2011) 1.00
Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol. CMAJ (2001) 1.00
[Plurisystematic degeneration of the neuraxis. Steele-Richardson-Olszewski syndrome]. Union Med Can (1965) 0.99
Letter: Diphasic dyskinesia during levodopa therapy. Lancet (1975) 0.99
The Quebec Cooperative Study of Friedreich's Ataxia: 1974-1984--10 years of research. Can J Neurol Sci (1984) 0.99
Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation (2001) 0.98
Smoking, alcohol consumption, lipid and lipoprotein levels. Can J Cardiol (1988) 0.98
The natural history of Machado-Joseph disease. An analysis of 138 personally examined cases. Can J Neurol Sci (1984) 0.97
Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis (1996) 0.97
Taurine in epilepsy. Lancet (1973) 0.97
Seizures in rats associated with divalent cation inhibition of NA + -K + -ATP'ase. Can J Biochem (1971) 0.97
Pyruvate metabolism in Friedreich's ataxia. Can J Neurol Sci (1976) 0.97
Familial periodic ataxia responsive to acetazolamide. Can J Neurol Sci (1984) 0.96
Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol (1987) 0.96
Electrocardiographic and vectocardiographic findings in Friedreich's ataxia. Can J Neurol Sci (1976) 0.95
Adverse clinical side effects of levodopa therapy. Contemp Neurol Ser (1971) 0.95
Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol (1993) 0.95
HLA and complement typing in olivo-ponto-cerebellar atrophy. Can J Neurol Sci (1978) 0.94
Echocardiographic findings in Friedreich's ataxia. Can J Neurol Sci (1976) 0.94
Parental ascent in the juvenile form of Huntington's chorea. Lancet (1970) 0.93
Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease. Can Med Assoc J (1972) 0.93
Pathology of the heart in Friedreich's ataxia: review of the literature and report of one case. Can J Neurol Sci (1976) 0.93
Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease. Neurology (1970) 0.92
Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms. J Neurol Sci (1981) 0.92
The clinical physiology of side effects in long-term L-DOPA therapy. Adv Neurol (1974) 0.92
Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens. Life Sci (1985) 0.91
A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol (2001) 0.91
Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci (1987) 0.91
Lysosomal enzymes in ataxia: discovery of two new cases of late onset hexosaminidase A and B deficiency (adult Sandhoff disease) in French Canadians. Can J Neurol Sci (1984) 0.91
Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol (1976) 0.90
Effects of intravenously administered digoxin on mild left ventricular failure in acute myocardial infarction in man. Am J Cardiol (1972) 0.90
Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study. Can Med Assoc J (1971) 0.90
Seven cases of Gilles de la tourette's syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci (1977) 0.90
Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man. Lancet (1975) 0.90
Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease. Neurology (1976) 0.90
Levodopa and presymptomatic detection of Huntington's disease--eight-year follow-up. N Engl J Med (1980) 0.89
Determination of Na + , K + , Mg 2+ , Cu 2+ , Zn 2+ , and Mn 2+ in rat brain regions. Can J Biochem (1973) 0.89